TYSON 2.0 Cannabis Expands Into Pennsylvania and Maryland: Inside Mike Tyson's Weed Empire

Mike Tyson's TYSON 2.0 has joined the small circle of celebrity cannabis brands actually pushing units at retail. The brand's late-March 2026 launch into Pennsylvania and Maryland via partner TerrAscend's Apothecarium dispensary chain — first announced on March 31 and rolling onto shelves through April and May — brings the heavyweight champion's products to two East Coast markets that together represent over $2 billion in annual cannabis sales. It is the most consequential celebrity-cannabis-brand state expansion of the year, and it pulls TYSON 2.0 ahead of most of its celebrity peers in a category where, for every Snoop or Seth Rogen success story, a half-dozen branded launches have quietly disappeared.

What makes the Tyson expansion notable is not the star wattage — celebrity cannabis brands have not been short on famous names. It is the operational discipline behind the launch: a tight partnership with a publicly traded multistate operator (TerrAscend), product SKUs tailored to each state's flower-vs.-vape preferences, and a measured pace that has avoided the overextension that sank earlier celebrity ventures.

What Launched Where

TerrAscend rolled out two distinct TYSON 2.0 lineups for the two new markets, each tuned to the state's regulatory and consumer profile.

In Pennsylvania, the launch SKUs include premium 3.5-gram and 28-gram flower jars alongside live resin disposable vape pens. Pennsylvania's medical-only market — which sold roughly $1.8 billion in 2025 — has a more conservative product mix than adjacent adult-use states, and the 28-gram jar in particular is a flower-heavy entry that fits the patient-purchasing pattern in PA dispensaries where patients tend to buy larger quantities less frequently.

In Maryland, the debut features 3.5-gram and 14-gram flower SKUs plus distillate vapes — a slightly different mix that reflects Maryland's adult-use market and the higher consumer turnover of smaller-format flower purchases. TerrAscend has indicated more product formats, including pre-rolls and edibles, will roll into both states throughout 2026.

Distribution at launch covered all Apothecarium locations across the two states, plus select TerrAscend wholesale partner dispensaries. TerrAscend operates 26 dispensaries across the U.S. and Canada, with concentration in the Northeast — making the chain a meaningful retail node for any East Coast cannabis brand looking to scale.

How TYSON 2.0 Got Here

TYSON 2.0 launched in 2021 with a single-state focus and a positioning that leaned hard on Tyson's personal cannabis-advocacy story — he has been one of the highest-profile public faces of cannabis legalization since exiting professional boxing, and his Tyson Ranch property in Southern California became an early cannabis-tourism destination. The brand's first three years were spent building licensing partnerships in individual state markets rather than attempting to operate as a true multistate company itself, a structural choice the cannabis industry calls the asset-light model.

The asset-light model works for celebrity cannabis because federal illegality prevents brands from owning licensed operations across state lines. A celebrity brand licenses its name, formulation guidance and marketing assets to a state-licensed cultivator/manufacturer in each market and collects a royalty. The local operator handles the actual cultivation, regulatory compliance, distribution and retail relationships. The model's biggest weakness — quality drift across states because each licensee uses different genetics, growing conditions and post-harvest practices — is also why TYSON 2.0's TerrAscend partnership is structurally different. By concentrating both the Pennsylvania and Maryland production with one multistate operator, Tyson's brand is buying more consistent flower quality than it could get from two separate single-state partners.

Where TYSON 2.0 Sells Now

After the Pennsylvania and Maryland additions, TYSON 2.0 products are available in dispensaries across more than a dozen U.S. states, including California, Nevada, Arizona, Massachusetts, Michigan, Colorado, Illinois, and now Pennsylvania and Maryland. The brand has also been expanding internationally — TYSON 2.0 announced a strategic retail expansion in Europe in January 2026, paired with Tyson's endorsement of the Marbella Cannabis Association movement in Spain. The international layer is unusual for a U.S. celebrity cannabis brand, most of which have struggled to clear regulatory and IP issues abroad.

The brand's product portfolio has also widened. The original lineup was flower-focused; the 2026 catalog includes flower, pre-rolls, vapes (both live resin and distillate), edibles (including the brand's signature ear-shaped Mike Bites gummies, a nod to the Holyfield fight that has become a marketing artifact), and in some markets, beverages. The breadth makes TYSON 2.0 one of the few celebrity cannabis brands operating with a portfolio comparable to mid-tier independent cannabis brands.

The Celebrity Cannabis Landscape in 2026

The Pennsylvania and Maryland launches put TYSON 2.0 in a leadership tier among celebrity cannabis brands that includes Snoop Dogg's Death Row Cannabis and Leafs by Snoop, Seth Rogen's Houseplant, Willie Nelson's Willie's Reserve, and Wiz Khalifa's Khalifa Kush. Beneath that tier, the celebrity cannabis category is more graveyard than ecosystem. Brands launched by everyone from Whoopi Goldberg to Carlos Santana to Jay-Z have wound down or shifted to limited niche distribution, often because the underlying state-by-state licensing economics did not pencil at small scale.

The brands that have lasted share three traits. They have a founder who is genuinely engaged with the product rather than just lending a name — Tyson is a self-described daily cannabis user who has been on TYSON 2.0 product development calls since the brand launched. They have aligned with operationally strong cannabis companies for licensing partnerships rather than chasing the highest-bidder partner in each state. And they have stayed within product categories where their personal credibility actually transfers — flower and pre-rolls for connoisseur-positioned brands like Death Row, premium edibles for design-driven brands like Houseplant, and a mix of formats for personality-driven brands like TYSON 2.0.

What This Tells Us About the East Coast Market

The Pennsylvania and Maryland launches matter for the East Coast cannabis story in a way that mainland operators have been watching. Pennsylvania is the country's biggest medical-only state and the most likely next mover into adult-use legalization. Maryland launched adult-use sales in mid-2023 and has been one of the more orderly market openings, posting roughly $1 billion in combined medical and adult-use sales in 2024 and exceeding that pace into 2025. TerrAscend has positioned itself as one of the dominant operators across the I-95 corridor from New Jersey through Maryland, and adding a marquee brand like TYSON 2.0 to that footprint is a competitive move against rival multistate operators looking to deepen their own East Coast brand portfolios.

For Pennsylvania patients in particular, the TYSON 2.0 launch lands at an interesting moment. The state remains medical-only, but adult-use legalization legislation is in committee and the May 18 primary results suggest more pro-cannabis legislators heading toward the fall session. Brands that establish strong patient relationships in the medical era tend to retain shelf space and consumer loyalty when adult-use launches. TYSON 2.0 entering Pennsylvania now is, in part, a positioning play for the larger market its operators expect to follow.

Will Celebrity Cannabis Still Matter in Five Years?

The structural challenge celebrity cannabis brands face — limited brand pricing power in a commoditizing flower market, asset-light economics that compress margins — has not gone away. What has changed is that the strongest celebrity brands have evolved beyond pure name-licensing into integrated cannabis lifestyle companies. Houseplant under Seth Rogen and Evan Goldberg has moved into housewares and design objects. Snoop Dogg's Death Row Cannabis has pulled in genetic IP partnerships with seed banks like Sensi Seeds. TYSON 2.0's playbook so far looks more brand-traditional, but the Marbella endorsement and European expansion suggest a 2026–27 pivot toward a broader cannabis lifestyle and advocacy footprint.

For consumers walking into an Apothecarium in Pennsylvania or Maryland this spring, the practical question is whether TYSON 2.0 is worth the premium over comparable in-house TerrAscend flower. Early reviews on cannabis-rating platforms suggest the flower is competently produced and well-cured but priced at a brand premium that may or may not be sustained as more product formats roll out and the launch novelty fades. For collectors and casual consumers who want a piece of cannabis-celebrity history, the Mike Bites gummies remain the brand's most distinctive product, and a 28-gram TYSON 2.0 flower jar in a Pennsylvania dispensary will, for at least the next year, count as one of the more interesting things to buy in that market.

Key Takeaways

• TYSON 2.0 launched in Pennsylvania and Maryland via TerrAscend's Apothecarium dispensary chain in late March 2026, marking the brand's most significant East Coast expansion.
• Pennsylvania launch SKUs include 3.5g and 28g flower jars plus live resin disposable vapes; Maryland features 3.5g and 14g flower plus distillate vapes.
• TYSON 2.0 is now in more than a dozen U.S. states plus European retail markets, putting it in a leadership tier of celebrity cannabis brands.
• The asset-light celebrity cannabis model works best when paired with one operationally strong multistate operator per region, which is what the TerrAscend partnership delivers.
• The Pennsylvania launch is a positioning play ahead of expected adult-use legalization in the country's largest medical-only cannabis market.

Explore cannabis news, find dispensaries, and join the community at Budpedia.